Nasser H. Hanna, MD, discusses the key takeaways on the current role of consolidation immunotherapy in patients with lung cancer, which has become standard in this setting. He highlights questions that still need to be addressed in this space.
Nasser H. Hanna, MD, a professor of Medicine at the Indiana University, discusses the key takeaways on the current role of consolidation immunotherapy in patients with lung cancer, which has become standard in this setting. He highlights questions that still need to be addressed in this space.
While many patients benefit from consolidation immunotherapy, some patients do not benefit. There is a group of patients who can do well with chemoradiation treatment alone, however, more work needs to be done to identify which patients should receive consolidation immunotherapy versus which patients receive sufficient benefit to cure their disease with chemoradiation alone, says Hanna. Consolidation immunotherapy is an important option for patients who will not receive benefit from the chemoradiation treatment.
Patients receive consolidation immunotherapy for a year, but Hanna questions if this is necessary for all patients. Some patients may only require 3 to 6 cycles of treatment as opposed to the full year on therapy, Hanna concludes.
<< View more resources and information regarding lung cancer
KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC
November 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More